Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 11:15:1785-1797.
doi: 10.2147/DMSO.S366967. eCollection 2022.

Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling

Yosef Tsegaye Dabi  1   2 , Sisay Teka Degechisa  1   3
Affiliations
Review

Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling

Yosef Tsegaye Dabi et al. Diabetes Metab Syndr Obes. .

Abstract

Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling.

Keywords: MODY; NDM; genome editing; monogenic diabetes; pluripotent stem cell.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in relation to this work.

Similar articles

See all similar articles

Cited by

References

    1. Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease. Diabetes Care. 2015;38(6):979–988. doi:10.2337/dc15-0144 - DOI - PMC - PubMed
    1. Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6(3):456. doi:10.4239/wjd.v6.i3.456 - DOI - PMC - PubMed
    1. Tallapragada DSP, Bhaskar S, Chandak GR. New insights from monogenic diabetes for “common” type 2 diabetes. Front Genet. 2015;6:251. doi:10.3389/fgene.2015.00251 - DOI - PMC - PubMed
    1. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol. 2021;22(11):751–771. doi:10.1038/s41580-021-00390-6 - DOI - PubMed
    1. Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM. New insights into K ATP channel gene mutations and neonatal diabetes mellitus. Nat Rev Endocrinol. 2020;16(7):378–393. doi:10.1038/s41574-020-0351-y - DOI - PubMed

LinkOut - more resources